34 Y Combinator companies in Industrial Bio, with team size, growth, open roles and funding.
Updated weekly, last on November 9, 2026. Roster from Y Combinator's public directory.
| Company | Batch | Team | 6 mo | 12 mo | Open roles | Total raised | Last round |
|---|---|---|---|---|---|---|---|
Our mission is to make biology easier to engineer. | S14Public | 487 | −7% | −24% | 1 | $1.6B | Grant$775M, Apr 2024 |
Decarbonizing the chemicals industry. | W17 | 133 | +2% | −1% | 0 | $856M | Debt$214M, Jun 2024 |
Next-generation DNA synthesis using enzymes | W20 | 82 | +5% | +21% | 7 | $130M | Series B$46.4M, Oct 2025 |
Robots that automate the everyday tasks of microbiologists. | W21 | 63 | 0 | $29.2M | Series A$20M, Apr 2024 | ||
We grow cells for biotech companies. | W18 | 63 | −19% | −18% | 1 | $102M | Series C$80M, Dec 2025 |
Unlocking the utility of genomics for the world. | W19 | 50 | −4% | 1 | $32.7M | Undisclosed round$12.7M, Jan 2024 | |
Robotic human cell manufacturing | S18 | 49 | +7% | 4 | $20.8M | Series A$19M, Nov 2023 | |
We make unmakeable proteins with radical advanced biomanufacturing. | S20 | 47 | +7% | +18% | 0 | $26.9M | Series A$8M, Jun 2025 |
Data analytics software for biomanufacturing. | W22 | 38 | −12% | −24% | YC | $20.6M | Seed$20.1M, Jul 2024 |
Clinically-validated ingredients from natural microbes | S20 | 32 | +23% | +23% | 3 | $26.4M | Series A$25M, Oct 2021 |
Shiru leverages ML to create proteins to feed the world sustainably. | S19 | 25 | 0% | −4% | 0 | $57M | Series B$16M, Nov 2024 |
Next-gen ingredients to decarbonize consumer products, starting w/… | S18 | 25 | −11% | −19% | 0 | $33.5M | Grant$1M, Jan 2024 |
Lygos (W16) built and commercialized sustainable, high-performance… | W16 | 22 | −45% | −60% | 0 | $213M | Grant$1.8M, Jul 2024 |
Enabling next generation medicines. A comprehensive platform and… | S18 | 21 | +5% | −5% | 0 | $59.5M | Series A$55M, Jan 2022 |
Rebellyous Foods is a food manufacturing technology and production… | S18 | 18 | +13% | +6% | 0 | $43.5M | Series B$2.4M, Jan 2025 |
Volumetric builds living multicellular tissues with a focus on the… | W20Acquired | 16 | −20% | −20% | 0 | $1.8M | Seed$1.8M, Jul 2020 |
Next-generation biocides for sustainable agriculture at scale | S24 | 15 | +15% | +67% | 0 | $500K | YC investment$500K, Sep 2024 |
Fermentation-derived natural products to solve health problems | S18 | 15 | +7% | +7% | 0 | $7.6M | Undisclosed round$7.5M, Oct 2022 |
Enzyme design models. | S24 | 11 | +22% | +10% | 0 | $500K | YC investment$500K, Jan 2026 |
Gen-AI Designed Enzymes for Pharmaceutical Innovation | W23 | 7 | +17% | +17% | 0 | $500K | YC investment$500K, Apr 2023 |
Impossible foods of seafood. | S20Acquired | 7 | 0% | 0% | 0 | $21.2M | Seed$18M, Jun 2022 |
We make bacteria and plants that clean up pollution. | S21 | 6 | 0% | −14% | 0 | $125K | Convertible note$125K, Oct 2024 |
Shiok Meats is a cell-based clean shrimp company, the first of its… | W19Acquired | 6 | −14% | −25% | 0 | $30.2M | Convertible note$10M, Jul 2021 |
Bioengineered kidneys for patients with kidney failure | W21 | 5 | −17% | −17% | 0 | $1M | Grant$1M, Jun 2023 |
Control lab instruments with natural language. | X26 | 4 | YC | ||||
Making 'REAL' Cow and Human Milk! | W22 | 4 | −20% | −20% | 0 | $2.4M | Seed$2.4M, Jun 2022 |
Synvivia applies chemical control over cell behavior | S16 | 4 | −20% | 0 | $376K | Grant$256K, Nov 2021 | |
AI infrastructure for biosecurity | S25 | 3 | 0 | ||||
Using DNA to store data. | S19 | 2 | 0 | $150K | YC investment$150K, Aug 2019 | ||
Rebuilding the drug discovery pipeline around agents | F26 | ||||||
Elevating mental health to be a part of your daily coffee ritual. | S20 | ||||||
dairy reinvented from plants | S18Inactive | ||||||
Using AI to predict biochemistry for manufacturing and therapeutics | W15Inactive | 0 | $2.2M | Seed$2.1M, May 2015 | |||
We design and build microbes to make chemicals greener at lower cost. | W15 |
Every launched company in YC's public directory, with its batch, status, industry and location. New companies show up the week YC lists them.
Each company is matched to Crustdata by its website. Crustdata adds team size and its change over 6 and 12 months, open roles from job postings, reported funding, and founders' past employers.
Hiring the most counts distinct roles posted in the last 60 days. Growth needs 10+ people today, shrinking 20+ a year ago, so tiny teams do not top the lists. Rebuilt every week.
The numbers on this page come from three Crustdata API calls. Crustdata tags 5,000+ companies with Y Combinator as an investor; swap the filter for any investor, industry or headcount range and track your own list, with founders' work emails one call away.
# 1. every company with Y Combinator as an investor curl https://api.crustdata.com/company/search \ -H "authorization: Bearer $CRUSTDATA_API_KEY" \ -H "x-api-version: 2025-11-01" \ -d '{ "filters": { "field": "funding.investors", "type": "in", "value": ["Y Combinator"] }, "fields": ["basic_info.name", "headcount.total", "headcount.growth_percent", "funding.total_investment_usd"], "limit": 100 }' # 2. open listings per company, last 60 days (limit 0 = counts only) curl https://api.crustdata.com/job/search \ -H "authorization: Bearer $CRUSTDATA_API_KEY" \ -H "x-api-version: 2025-11-01" \ -d '{ "filters": { "op": "and", "conditions": [ { "field": "company.basic_info.company_id", "type": "in", "value": [...] }, { "field": "metadata.date_added", "type": "=>", "value": "2026-08-24" } ]}, "limit": 0, "aggregations": [{ "type": "group_by", "field": "company.basic_info.company_id", "agg": "count" }] }' # 3. the same company filter as a weekly watch: POST /watch/company/search
34 Y Combinator companies are in Industrial Bio; 28 are active.
6 companies posted roles in the last 60 days, led by Ansa Biotechnologies (7 roles), Mytos (4 roles) and Kingdom (3 roles). 6 mark themselves as hiring on YC's directory.
By team growth over 6 months (10+ people): Kingdom (+23%), Ligo Biosciences (+22%) and ACX (+15%).
Largest latest rounds in the last 12 months, after their YC batch: Culture Biosciences ($80M).